According to a recent retrospective study, (S Singh et al. Clin Gastroenterol Hepatol 2016; 14: 1120-29), infliximab outperformed its rivals. In the spirit of the recent olympics, we’ll give infliximab a gold medal in the anti-TNF category.
Here’s the play-by-play:
This study used an administrative claims database with more than 100 million US enrollees. In total, there were 3205 biologic-naive patients with Crohn’s disease (CD) with a mean age of 41 years. All of the participants had not received a biologic agent for at least 12 months prior to their first study dose (between 2006-2014). In addition, the authors excluded patients who had a concomitant diagnosis which could necessitate a biologic, including rheumatoid arthritis, ankylosing spondylitis, and psoriasis.
- Compared to adalimumab-treated patients, inlfiximab-treated patients had a lower risk of CD-related hospitalization (aHR [adjusted Hazard Ratio] 0.80), abdominal surgery (aHR 0.76), and corticosteroid use (aHR 0.85)
- Compared to certolizumab pegol-treated patients, infliximab-treated patients had a lower risk of hospitalization (all-cause) (aHR 0.70), and CD-related hospitalization (aHR 0.59).
- All agents had comparable risk of serious infections
Was this a fair race (ie study)? Definitely. If anything, this study may have underestimated the benefit of infliximab. Due to trouble with confounders across retrospective studies, it may be that infliximab was chosen preferentially among sicker patients.
My take: There is limited data on comparative effectiveness of anti-TNF agents. This retrospective study indicates that infliximab is likely superior to its competitors. Definitive proof would necessitate a head-to-head live-action (prospective) competition.
Related blog posts:
- Comparing Biologics for Ulcerative Colitis | gutsandgrowth
- Head-to-Head: Nutritional Therapy versus Biological … – gutsandgrowth
- Adalimumab for children with Crohn’s disease | gutsandgrowth
- Should All Pediatric Patients with Crohn’s Disease … – gutsandgrowth
- What is Your Infliximab Adherence Rate? | gutsandgrowth